BCT and BCTXL Related Headlines
Go Back- BriaCell Therapeutics Announces Pricing of Offering
- BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
- BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
- BriaCell adds Penn Medicine cancer center to phase 3 breast cancer trial
- BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell enrolls over 230 patients in phase 3 breast cancer study
- BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
- BriaCell adds NYU cancer center to phase 3 breast cancer trial
- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
- BriaCell presents cancer therapy data at 2026 AACR meeting
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell reports extended survival in metastatic breast cancer trial
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell completes $30 million public offering of units
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell prices $30 million public offering at $5.59 per unit
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering
BCT and BCTXL Related Press Releases
Go Back- BriaCell Therapeutics Announces Pricing of Offering
- BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
- BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
- BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering
